Suppr超能文献

减低预处理强度的异基因干细胞移植后高剂量每周一次脂质体两性霉素B抗真菌预防治疗

High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.

作者信息

El-Cheikh J, Faucher C, Fürst S, Duran S, Berger P, Vey N, Stoppa A-M, Bouabdallah R, Gastaut J-A, Viens P, Blaise D, Mohty M

机构信息

Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France.

出版信息

Bone Marrow Transplant. 2007 Mar;39(5):301-6. doi: 10.1038/sj.bmt.1705592. Epub 2007 Jan 29.

Abstract

The use of high-dose corticosteroids for graft-versus-host disease (GVHD) treatment represents a major risk factor for long-term invasive fungal infections. The aim of this study was to investigate the safety and tolerance of weekly prophylactic administration of once-weekly high-dose (7.5 mg/kg) of liposomal amphotericin B (L-AmB) therapy in 21 adult patients receiving high-dose prednisone (2 mg/kg/day) for acute GVHD therapy after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT). Patients received a median of 4 (range, 1-8) infusions of L-AmB. Seven patients (33%; 95% confidence intervals (CI), 13-53%) discontinued taking the study drug owing to study drug-related adverse events, including elevated serum creatinine (>1.5 times from baseline values; n=5), hypotension and pain (n=1), and violent chest pain and arrhythmia (n=1). The overall frequency of infusion-related reactions was 29% (n=6; 95% CI, 10-48%), but these reactions were always transient and relieved by stopping the infusion. This safety data provide support for an efficacy study of this prophylaxis strategy, because this may help further improving the outcome of RIC or nonmyeloablative allo-SCT.

摘要

使用大剂量皮质类固醇治疗移植物抗宿主病(GVHD)是长期侵袭性真菌感染的主要危险因素。本研究旨在调查21例接受大剂量泼尼松(2mg/kg/天)治疗急性GVHD的成年患者,在接受降低强度预处理(RIC)的异基因干细胞移植(allo-SCT)后,每周预防性给予一次大剂量(7.5mg/kg)脂质体两性霉素B(L-AmB)治疗的安全性和耐受性。患者接受L-AmB输注的中位数为4次(范围1-8次)。7例患者(33%;95%置信区间(CI),13-53%)因与研究药物相关的不良事件而停止服用研究药物,包括血清肌酐升高(>基线值的1.5倍;n=5)、低血压和疼痛(n=1)以及剧烈胸痛和心律失常(n=1)。输注相关反应的总体发生率为29%(n=6;95%CI,10-48%),但这些反应总是短暂的,通过停止输注即可缓解。这些安全性数据为该预防策略的疗效研究提供了支持,因为这可能有助于进一步改善RIC或非清髓性allo-SCT的治疗结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验